UNSPSC 51172148: Rociverine

This classification denotes an antispasmotic agent with the molecular formula C20H37NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VI08KS44V0, chemically known as (1,1-bicyclohexyl)-2-carboxylic acid, 1-hydroxy-, 2-(diethylamino)-1-methylethyl ester but generally known as rociverine, which bears US NIH Compound Identifier 68705. European Medicines Agency schedules Rociverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10352MIG.

UNSPSC 51172148 Rociverine is a Commodity code covering pharmaceutical substances and their derivatives procured by state and local health, criminal justice, and benefit administration agencies. Recent state and local solicitations show demand for both direct pharmaceutical supply (generic multi-source drugs and over-the-counter products distributed through established wholesaler networks) and specialized pharmaceutical services including specimen collection, drug testing, and prescription fulfillment innovation. State and local buyers under this code include state health and human services departments, cooperative purchasing alliances spanning multiple states, county criminal justice agencies, and implicit participation by state employee health plans and local government facilities receiving pharmaceutical products through state and cooperative agreements.

Geographic activity centers on Texas and the Upper Midwest. The Texas Health and Human Services Commission issued a Request for Information in April 2026 regarding direct-to-manufacturer prescription programs, while Collin County Community Supervision and Corrections Department posted an RFP in July 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term with optional three one-year renewals commencing September 1, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply participating state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and maintain cGMP and DSCSA compliance with performance penalties for late reporting or operational failures. Evaluation criteria vary by solicitation type: the Collin County RFP weights vendor understanding, firm qualifications, client references, and cost equally at 30 points each with optional Phase 2 demonstrations; the MMCAP RFP emphasizes price competitiveness at 75 percent with administrative compliance and EDI capability as secondary factors.